CSG N.V.: 17% Revenue Growth, 45% Stock Decline — Valuation Reset Outpaces Business Slowdown

CSG N.V. (Czechoslovak Group, CSG.AS) posted H1 2026 revenue of €3.25 billion, up 17.2% year-over-year, and reaffirmed its full-year 2026 guidance. That is a business running. Yet the stock is down roughly 45% from its 52-week high of €35.50, trading around €18.44 on Euronext Amsterdam as of August 5. Market cap has compressed to roughly €18.5 billion. The key question for the investor isn't whether CSG is growing — it clearly is — but whether the valuation reset has already outpaced whatever business deterioration the market is pricing in. My reading: the multiple has done a lot of the work. The stock is not a screaming bargain, but the risk/reward at €18 sits closer to buy territory than hold.

What changed, and why the stock fell

CSG IPO'd on January 23, 2026, surging more than 30% on its Amsterdam debut amid a wave of European defense enthusiasm. It climbed to €35.50 within months as the post-Ukraine security spending narrative carried defense names across the continent. Then the pullback came. Defense stocks as a group have faced headwinds from budget uncertainty, contracting timelines, and the realization that government procurement cycles don't accelerate on sentiment alone. CSG also carries specific risks: it's a relatively young public company with limited operating history as a listed entity, its revenue is heavily concentrated in sovereign and military customers, and its geographic footprint — anchored in the Czech Republic and Slovakia — exposes it to Central European political dynamics.

The 45% drawdown from the high isn't a company-specific collapse. It's a multiple contraction on a sector that ran too hard, too fast. But that distinction matters for the investor. Multiple compression on a still-growing business is a different animal than multiple compression on a deteriorating one.

The operating numbers: growth is intact

The H1 2026 release, published August 7, tells a straightforward growth story. Revenue of €3.25 billion, up 17.2% year-over-year. Management reaffirmed FY 2026 guidance, signaling no mid-cycle course correction. The group's results statement emphasized "continued strong growth across core markets" — referring to its three main pillars: firearms and ammunition for the civilian market, military ammunition systems, and broader defense and security equipment.

CSG has also been strengthening its leadership team and developing positions in advanced technologies, which points to strategic positioning beyond its traditional small-caliber ammunition and firearms heritage. The company recently transferred propellant production technology to a Polish partner, deepening its footprint in the Polish defense ecosystem — one of the most actively expanding in Europe.

What the results statement doesn't give us in detail is operating margin, EBITDA, or free cash flow. That's a data gap. CSG's limited time as a public company means its disclosure depth is still evolving, and full granular profitability metrics weren't available in the H1 release language I was able to access. For an investor, that's a real limitation: you can see the top-line growth but you can't fully verify how much of it flows through to cash earnings. I'm factoring that uncertainty into the assessment.

Valuation versus growth: the multiple has done the work

At €18.44 and €18.5 billion market cap, CSG trades at roughly 5.7x trailing revenue based on the latest four quarters of reported data (the H1 2026 run rate of €3.25 billion annualizes to €6.5 billion, implying a forward revenue multiple around 2.8x). For a company growing revenue at 17% with a dominant position in European firearms and military ammunition manufacturing, and with a long list of sovereign customers across NATO and non-NATO defense budgets, that forward multiple is not rich.

The 52-week high of €35.50 implied a market cap near €35 billion — roughly 5.4x the H1 run rate. The market has effectively halved the multiple it was willing to pay for the same business. Revenue growth didn't slow by 45%. Operating margins haven't collapsed by 45% (again, those figures remain opaque, but management's reaffirmation of guidance argues against a fundamental breakdown). The multiple did the compression.

For context, CSG is one of the largest publicly traded European defense manufacturers focused on small-arms and ammunition. Direct peer comparisons are imperfect — Rheinmetall, BAE Systems, and KNDS trade on different business mixes, geographies, and market structures — but the general principle holds: European defense primes with government backlogs and multi-year growth visibility typically command forward revenue multiples well above 2x when the macro environment supports defense spending. CSG at roughly 2.8x forward revenue, with 17% top-line growth and reaffirmed guidance, is not priced for perfection. It's priced for skepticism.

The catalyst clock

Near-term catalysts are fairly clear:

• H2 2026 results and full-year close: The reaffirmed FY 2026 guidance gives a concrete yardstick. If CSG delivers against or beats that guidance while margins prove durable, the current multiple looks backward-looking.
• European defense budget trajectory: The EU's push for 2% of GDP on defense and national programs expanding ammunition stockpiles create a multi-year demand tailwind. CSG is a primary supplier for this cycle.
• Polish and Central European procurement: The Polish defense expansion — one of the fastest in Europe — is a direct channel for CSG products through existing partnerships and technology transfer arrangements.
• Leadership and governance maturation: A strengthening leadership team and improving public-company disclosure practices reduce the "new issuer" discount over time.

Risks that could break the thesis

This is not a risk-free entry. Three risks warrant active monitoring:

• Profitability opacity: Without clear operating margin and free cash flow figures, the growth story is only half-verified. If H2 or FY 2026 results reveal thin margins or heavy reinvestment burdens, the forward revenue multiple won't look cheap enough.
• Sovereign customer concentration: Government procurement can stall, shift, or face political reversal. A slowdown in key-country orders would hit CSG harder than a diversified commercial name.
• Geopolitical normalization: If the European security environment stabilizes faster than expected, defense budget momentum could soften. CSG is a cyclical beneficiary of heightened tensions, not just a structural growth story.

Investor takeaway

CSG N.V. is a growth story that got punished by multiple compression. Revenue is up 17.2%, guidance is reaffirmed, and the stock trades at a forward revenue multiple that assumes execution risk without yet proving the margin story. I wouldn't call this a panic-buy situation — the defense sector pullback has real policy and cyclical underpinnings. But the business hasn't deteriorated anywhere near as fast as the stock price.

The next H2 2026 results and full-year close are the inflection point. If margins hold and revenue tracks the reaffirmed guidance, the current valuation looks like a lagging indicator. If margins disappoint or guidance resets downward, the skepticism was warranted.

At €18, the setup leans toward buy for investors with a six-to-12-month horizon and tolerance for defense-sector policy risk. The risk/reward has tilted. The clock is set for H2.